Furthermore, suppression of GBA1 using siRNA induced paclitaxel resistance and the activation of the AKT pathway in three different cancer cell lines, including colon carcinoma, breast adenocarcinoma, and non-small-cell lung carcinoma [37]. Here, AKT1 is linked to breast adenocarcinoma.